A number of leaders in the pharmaceutical industry are calling the potential exit of Great Britain from the European Union "a mistake," reports the Financial Times. The "Brexit," as it is commonly referred to, would have less of an immediate impact on sales as it would on drug discovery, according to these executives. But it would still lead to an overall negative outcome.
